225 MAIN ST STE 15 WENHAM, MA 01984 Get Directions
225 MAIN ST STE 15 WENHAM, MA 01984 Get Directions
Based in the Massachusetts biotech and medtech hub, Elucid Bioimaging is organized to pursue projects and activities for the advancement of medicine. Societal pressure on the one hand, and enabling technology capabilities on the other, is transforming the landscape both as it is used in the clinic as well as utilized in drug development. Specifically, increasingly sophisticated biomedical signal and image exploitation approaches optimize the utlilization of technology to create solutions in improved cost effectiveness, diagnostic and therapeutic ability, and improved patient outcomes.
However, these opportunities require a different approach: disease or health concern must be considered first, with application of appropriate technology being driven by it as opposed to the other way around. Additionally, there is increasing ability and need for analytic processing of acquired data, even as the underlying platform capabilities also expand. A particularly active example is the shift of in-vivo imaging from its historic roots as a subjective/qualitative discipline to a quantitative anaytical measurement method with increasingly capable computational results.
Our slogan is "Realizing the Power of Imaging in Medicine." Help us understand what you are working to achieve and we look forward to working together to achieve it.
At Elucid, our mission is to advance quantitative imaging and integrative medical science for the benefit of patients. We develop products and services to better inform medical decisions and manage individual patients and to improve the effectiveness of clinical trials of novel therapies.
Our revolutionary development platform QI-Bench provides the means for rigorously exploiting potentially massive data sets to transform radiological imaging for the 21st century with reproducible science.
Our flagship atherosclerosis product vascuCAP(TM) challenges the status quo by thinking differently to provide the world's burgeoning baby boomer population with a non-invasive and effective biomarker that stratifies dangerous atherosclerotic plaques to save lives and reduce disability due to stroke and heart attack.
© Dun & Bradstreet, Inc. 2024. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.